share_log

ST百灵(002424.SZ):全资子公司糖宁通络片临床试验申请获得批准

ST Bailing (002424.SZ): The application for clinical trial of Tanging Tongluo片 by its wholly-owned subsidiary has been approved.

Gelonghui Finance ·  Nov 12 02:36

On November 12, GeLongHui reported that on November 12, 2024, the company's wholly-owned subsidiary, BeLingYuxiu (Zhuhai) Pharmaceutical Co., Ltd. (referred to as 'BeLingYuxiu'), received the 'Drug Clinical Trial Approval Notification Letter' issued by the National Medical Products Administration (NMPA) (Notification No.: 2024LP02560). The clinical trial application for Tongning Tongluo tablets submitted by BeLingYuxiu has been approved, allowing the product to conduct Phase III clinical trials for diabetic retinopathy.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment